Glycorex Transplantation AB (NGM:GTAB B) Cyclically Adjusted FCF per Share: kr-0.01 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NGM:GTAB B Glycorex Transplantation AB NGM:GTAB B
59 GF Score
Price kr1.41
GF Value kr1.81
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Glycorex Transplantation AB Cyclically Adjusted FCF per Share?

Glycorex Transplantation AB NGM:GTAB B -0.70% 59 Cyclically Adjusted FCF per Share is kr-0.01 as of Mar. 2026. GuruFocus rates NGM:GTAB B with a GF Score™ of 59/100 and a GF Value™ of kr1.81 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Glycorex Transplantation AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was kr-0.013. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr-0.01 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-20), Glycorex Transplantation AB's current stock price is kr1.41. Glycorex Transplantation AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was kr-0.01. Glycorex Transplantation AB's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Glycorex Transplantation AB was 444.00. The lowest was 390.00. And the median was 407.50.


Glycorex Transplantation AB  (NGM:GTAB B) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Glycorex Transplantation AB was 444.00. The lowest was 390.00. And the median was 407.50.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Glycorex Transplantation AB Cyclically Adjusted FCF per Share Related Terms


Glycorex Transplantation AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Glycorex Transplantation AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glycorex Transplantation AB Cyclically Adjusted FCF per Share Chart

Glycorex Transplantation AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.01 -0.01 -0.01 0.00

Glycorex Transplantation AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 0.00 0.00 0.00 -0.01

NGM:GTAB B vs VRTX, REGN, RVMD: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Glycorex Transplantation AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glycorex Transplantation AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Glycorex Transplantation AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Glycorex Transplantation AB's Cyclically Adjusted Price-to-FCF falls into.


NGM:GTAB B
59GF Score
Glycorex Transplantation AB NGM:GTAB B
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glycorex Transplantation AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Glycorex Transplantation AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.013/133.5600*133.5600
=-0.013

Current CPI (Mar. 2026) = 133.5600.

Glycorex Transplantation AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.013 101.019 0.017
201609 -0.024 101.138 -0.032
201612 0.040 102.022 0.052
201703 -0.006 102.022 -0.008
201706 -0.007 102.752 -0.009
201709 0.011 103.279 0.014
201712 0.041 103.793 0.053
201803 -0.012 103.962 -0.015
201806 0.008 104.875 0.010
201809 -0.015 105.679 -0.019
201812 0.037 105.912 0.047
201903 -0.012 105.886 -0.015
201906 0.014 106.742 0.018
201909 0.068 107.214 0.085
201912 0.014 107.766 0.017
202003 0.035 106.563 0.044
202006 -0.062 107.498 -0.077
202009 0.023 107.635 0.029
202012 -0.005 108.296 -0.006
202103 -0.039 108.360 -0.048
202106 0.006 108.928 0.007
202109 0.006 110.338 0.007
202112 -0.016 112.486 -0.019
202203 -0.055 114.825 -0.064
202206 0.015 118.384 0.017
202209 -0.009 122.296 -0.010
202212 0.012 126.365 0.013
202303 -0.055 127.042 -0.058
202306 -0.063 129.407 -0.065
202309 -0.038 130.224 -0.039
202312 -0.021 131.912 -0.021
202403 -0.001 132.205 -0.001
202406 -0.026 132.716 -0.026
202409 0.014 132.304 0.014
202412 0.014 132.987 0.014
202503 0.019 132.825 0.019
202506 -0.009 133.699 -0.009
202509 0.003 133.480 0.003
202512 0.018 133.390 0.018
202603 -0.013 133.560 -0.013

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of kr-0.01 mean?
Glycorex Transplantation AB (NGM:GTAB B) has a Cyclically Adjusted FCF per Share of kr-0.01 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Glycorex Transplantation AB and its competitors.
Is Glycorex Transplantation AB's Cyclically Adjusted FCF per Share too high?
Glycorex Transplantation AB's current Cyclically Adjusted FCF per Share is kr-0.01. Overall, Glycorex Transplantation AB has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Glycorex Transplantation AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Glycorex Transplantation AB's Cyclically Adjusted FCF per Share of kr-0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Glycorex Transplantation AB and its competitors. Glycorex Transplantation AB's current Cyclically Adjusted FCF per Share is kr-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glycorex Transplantation AB stock overvalued right now?
Based on GuruFocus' analysis, Glycorex Transplantation AB (NGM:GTAB B) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.81, compared to a current price of kr1.41 — trading 22.1% below its estimated fair value. The current Cyclically Adjusted FCF per Share is kr-0.01. Glycorex Transplantation AB's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Glycorex Transplantation AB (NGM:GTAB B), the current Cyclically Adjusted FCF per Share is kr-0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glycorex Transplantation AB (NGM:GTAB B) Overvalued in 2026?

Based on GuruFocus' analysis, Glycorex Transplantation AB stock appears to be undervalued. The current stock price of kr1.41 is trading 22.1% below its estimated GF Value™ of kr1.81. GuruFocus considers Glycorex Transplantation AB to be Modestly Undervalued.

Key valuation signals for NGM:GTAB B:

  • Cyclically Adjusted FCF per Share: kr-0.01
  • GF Value™: kr1.81 vs. price of kr1.41 (22.1% below fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the NGM:GTAB B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Glycorex Transplantation AB Business Description

Other Exchanges O33:Germany
Address Scheelevagen 27, Lund, SWE, 223 63
Glycorex Transplantation AB is a medical technology company. Its main product Glycosorb ABO is used clinically in six continents to facilitate blood group incompatible transplants, especially in kidney transplants from related living donors, but also in transplantation of liver, heart, lung and stem cells. Glycosorb ABO enables grafts regardless of the blood group of donors and recipients. The product is used in extracorporeal blood treatment, that is, a blood treatment that takes place outside the body in the same way as dialysis. Its segment is research, develop, manufacture, market and sell products in the field of organ transplantation or related areas. Geographically it operates in Europe, Australia, Singapore, India, and Other countries with majority of revenue from Europe.
59GF Score

Get the complete analysis for NGM:GTAB B

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.41
Price
kr1.81
GF Value